Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 2;68(7):1462–1472. doi: 10.2337/db18-1175

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

PMC Copyright notice

Cisterna magna administration of FGF1 improved metabolic outcomes in db/db mice. Daily blood glucose levels (A), plasma insulin (B), and food intake (C) after a single cisterna magna injection of FGF1 (filled squares, 3 µg, n = 5) or vehicle (open squares, n = 6) in db/db mice. D: GSIS 6 days after cisterna magna administration of FGF1 or vehicle. E: c-Fos activation of third ventricle tanycytes 90 min after cisterna magna administration of FGF1 (filled bars, F, n = 3) or vehicle (open bars, V, n = 3). Arrows represent injection time course. Data are expressed as mean ± SEM. P values were determined by two-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; #P < 0.05 for overall treatment effect. d, days; m, minutes.